FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2109176076> ?p ?o ?g. }

• W2109176076 endingPage "1121" @default.
• W2109176076 startingPage "1116" @default.
• W2109176076 abstract "Results from the phase III trial CLEOPATRA in human epidermal growth factor receptor 2-positive first-line metastatic breast cancer demonstrated significant improvements in progression-free and overall survival with pertuzumab, trastuzumab, and docetaxel over placebo, trastuzumab, and docetaxel. We carried out exploratory analyses of the incidence and time to development of central nervous system (CNS) metastases in patients from CLEOPATRA.Patients received pertuzumab/placebo: 840 mg in cycle 1, then 420 mg; trastuzumab: 8 mg/kg in cycle 1, then 6 mg/kg; docetaxel: initiated at 75 mg/m(2). Study drugs were administered i.v. every 3 weeks. The log-rank test was used for between-arm comparisons of time to CNS metastases as first site of disease progression and overall survival in patients with CNS metastases as first site of disease progression. The Kaplan-Meier approach was used to estimate median time to CNS metastases as first site of disease progression and median overall survival.The incidence of CNS metastases as first site of disease progression was similar between arms; placebo arm: 51 of 406 (12.6%), pertuzumab arm: 55 of 402 (13.7%). Median time to development of CNS metastases as first site of disease progression was 11.9 months in the placebo arm and 15.0 months in the pertuzumab arm; hazard ratio (HR) = 0.58, 95% confidence interval (CI) 0.39-0.85, P = 0.0049. Overall survival in patients who developed CNS metastases as first site of disease progression showed a trend in favor of pertuzumab, trastuzumab, and docetaxel; HR = 0.66, 95% CI 0.39-1.11. Median overall survival was 26.3 versus 34.4 months in the placebo and pertuzumab arms, respectively. Treatment comparison of the survival curves was not statistically significant for the log-rank test (P = 0.1139), but significant for the Wilcoxon test (P = 0.0449).While the incidence of CNS metastases was similar between arms, our results suggest that pertuzumab, trastuzumab, and docetaxel delays the onset of CNS disease compared with placebo, trastuzumab, and docetaxel.NCT00567190." @default.
• W2109176076 created "2016-06-24" @default.
• W2109176076 creator A5004300577 @default.
• W2109176076 creator A5012884004 @default.
• W2109176076 creator A5029812588 @default.
• W2109176076 creator A5051629490 @default.
• W2109176076 creator A5063569717 @default.
• W2109176076 creator A5067203408 @default.
• W2109176076 creator A5089465499 @default.
• W2109176076 date "2014-06-01" @default.
• W2109176076 modified "2023-10-14" @default.
• W2109176076 title "Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA" @default.
• W2109176076 cites W1925211454 @default.
• W2109176076 cites W1967930333 @default.
• W2109176076 cites W1969411102 @default.
• W2109176076 cites W1976628810 @default.
• W2109176076 cites W1992137963 @default.
• W2109176076 cites W1999476814 @default.
• W2109176076 cites W2012784647 @default.
• W2109176076 cites W2013669698 @default.
• W2109176076 cites W2026266923 @default.
• W2109176076 cites W2040584772 @default.
• W2109176076 cites W2042874073 @default.
• W2109176076 cites W2044702943 @default.
• W2109176076 cites W2045134790 @default.
• W2109176076 cites W2056030302 @default.
• W2109176076 cites W2057691996 @default.
• W2109176076 cites W2063083613 @default.
• W2109176076 cites W2063376924 @default.
• W2109176076 cites W2115425452 @default.
• W2109176076 cites W2120661754 @default.
• W2109176076 cites W2129749518 @default.
• W2109176076 cites W2130735457 @default.
• W2109176076 cites W2138001521 @default.
• W2109176076 cites W2141590659 @default.
• W2109176076 cites W2143184226 @default.
• W2109176076 cites W2144686284 @default.
• W2109176076 cites W2162155075 @default.
• W2109176076 cites W2163797857 @default.
• W2109176076 cites W2166199281 @default.
• W2109176076 cites W2168814163 @default.
• W2109176076 cites W2288763477 @default.
• W2109176076 cites W4211086468 @default.
• W2109176076 doi "https://doi.org/10.1093/annonc/mdu133" @default.
• W2109176076 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4037862" @default.
• W2109176076 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24685829" @default.
• W2109176076 hasPublicationYear "2014" @default.
• W2109176076 type Work @default.
• W2109176076 sameAs 2109176076 @default.
• W2109176076 citedByCount "177" @default.
• W2109176076 countsByYear W21091760762014 @default.
• W2109176076 countsByYear W21091760762015 @default.
• W2109176076 countsByYear W21091760762016 @default.
• W2109176076 countsByYear W21091760762017 @default.
• W2109176076 countsByYear W21091760762018 @default.
• W2109176076 countsByYear W21091760762019 @default.
• W2109176076 countsByYear W21091760762020 @default.
• W2109176076 countsByYear W21091760762021 @default.
• W2109176076 countsByYear W21091760762022 @default.
• W2109176076 countsByYear W21091760762023 @default.
• W2109176076 crossrefType "journal-article" @default.
• W2109176076 hasAuthorship W2109176076A5004300577 @default.
• W2109176076 hasAuthorship W2109176076A5012884004 @default.
• W2109176076 hasAuthorship W2109176076A5029812588 @default.
• W2109176076 hasAuthorship W2109176076A5051629490 @default.
• W2109176076 hasAuthorship W2109176076A5063569717 @default.
• W2109176076 hasAuthorship W2109176076A5067203408 @default.
• W2109176076 hasAuthorship W2109176076A5089465499 @default.
• W2109176076 hasBestOaLocation W21091760761 @default.
• W2109176076 hasConcept C121608353 @default.
• W2109176076 hasConcept C126322002 @default.
• W2109176076 hasConcept C143998085 @default.
• W2109176076 hasConcept C207103383 @default.
• W2109176076 hasConcept C2775930923 @default.
• W2109176076 hasConcept C2779786085 @default.
• W2109176076 hasConcept C2781164504 @default.
• W2109176076 hasConcept C2781190966 @default.
• W2109176076 hasConcept C44249647 @default.
• W2109176076 hasConcept C530470458 @default.
• W2109176076 hasConcept C71924100 @default.
• W2109176076 hasConceptScore W2109176076C121608353 @default.
• W2109176076 hasConceptScore W2109176076C126322002 @default.
• W2109176076 hasConceptScore W2109176076C143998085 @default.
• W2109176076 hasConceptScore W2109176076C207103383 @default.
• W2109176076 hasConceptScore W2109176076C2775930923 @default.
• W2109176076 hasConceptScore W2109176076C2779786085 @default.
• W2109176076 hasConceptScore W2109176076C2781164504 @default.
• W2109176076 hasConceptScore W2109176076C2781190966 @default.
• W2109176076 hasConceptScore W2109176076C44249647 @default.
• W2109176076 hasConceptScore W2109176076C530470458 @default.
• W2109176076 hasConceptScore W2109176076C71924100 @default.
• W2109176076 hasIssue "6" @default.
• W2109176076 hasLocation W21091760761 @default.
• W2109176076 hasLocation W21091760762 @default.
• W2109176076 hasLocation W21091760763 @default.
• W2109176076 hasLocation W21091760764 @default.
• W2109176076 hasOpenAccess W2109176076 @default.
• W2109176076 hasPrimaryLocation W21091760761 @default.

• next